Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryohei Katayama

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|June 19, 2007
Impairment of the ubiquitin-proteasome system by cellular FLIPToshiyasu Ishioka, Ryohei Katayama, Ryo Kikuchi, et al.
The Journal of Biological Chemistry|November 11, 2010
Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinaseDaisuke Morishita, Miho Takami, Seiko Yoshikawa, et al.
Nature Cell Biology|August 10, 2004
Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection functionYanyan Hao, Keiko Sekine, Atsushi Kawabata, et al.
Life Science Alliance|May 4, 2022
Systematic identification of ALK substrates by integrated phosphoproteome and interactome analysisJun Adachi, Akemi Kakudo, Yoko Takada, et al.
NPJ Precision Oncology|March 18, 2022
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancerYuki Shimizu, Koutaroh Okada, Jun Adachi, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 12, 2023
Ultra-Rapid and Specific Gelation of Collagen Molecules for Transparent and Tough Gels by Transition Metal ComplexationTomoyuki Suezawa, Naoko Sasaki, Yuichi Yukawa, et al.
Thoracic Cancer|January 17, 2020
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancerKen Takahashi, Yosuke Seto, Koutaroh Okada, et al.
Cancer Science|July 12, 2023
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trialTatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor TreatmentHiromi Furuta, Mitsugu Araki, Katsuhiro Masago, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|June 19, 2007
Impairment of the ubiquitin-proteasome system by cellular FLIPToshiyasu Ishioka, Ryohei Katayama, Ryo Kikuchi, et al.
The Journal of Biological Chemistry|November 11, 2010
Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinaseDaisuke Morishita, Miho Takami, Seiko Yoshikawa, et al.
Nature Cell Biology|August 10, 2004
Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection functionYanyan Hao, Keiko Sekine, Atsushi Kawabata, et al.
Life Science Alliance|May 4, 2022
Systematic identification of ALK substrates by integrated phosphoproteome and interactome analysisJun Adachi, Akemi Kakudo, Yoko Takada, et al.
NPJ Precision Oncology|March 18, 2022
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancerYuki Shimizu, Koutaroh Okada, Jun Adachi, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 12, 2023
Ultra-Rapid and Specific Gelation of Collagen Molecules for Transparent and Tough Gels by Transition Metal ComplexationTomoyuki Suezawa, Naoko Sasaki, Yuichi Yukawa, et al.
Thoracic Cancer|January 17, 2020
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancerKen Takahashi, Yosuke Seto, Koutaroh Okada, et al.
Cancer Science|July 12, 2023
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trialTatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor TreatmentHiromi Furuta, Mitsugu Araki, Katsuhiro Masago, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Pageof 11